These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20187712)

  • 1. Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis.
    Lagoumintzis G; Zisimopoulou P; Kordas G; Lazaridis K; Poulas K; Tzartos SJ
    Autoimmunity; 2010 Aug; 43(5-6):436-45. PubMed ID: 20187712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel therapies for MG: Studies in animal models.
    Souroujon MC; Brenner T; Fuchs S
    Autoimmunity; 2010 Aug; 43(5-6):446-60. PubMed ID: 20298126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency.
    Kostelidou K; Trakas N; Tzartos SJ
    J Neuroimmunol; 2007 Oct; 190(1-2):44-52. PubMed ID: 17764755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains.
    Zisimopoulou P; Lagoumintzis G; Poulas K; Tzartos SJ
    J Neuroimmunol; 2008 Aug; 200(1-2):133-41. PubMed ID: 18603305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.
    Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P
    Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.
    Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ
    J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-specific apheresis of autoantibodies in myasthenia gravis.
    Lazaridis K; Zisimopoulou P; Lagoumintzis G; Skriapa L; Trakas N; Evangelakou P; Kanelopoulos I; Grapsa E; Poulas K; Tzartos S
    Ann N Y Acad Sci; 2012 Dec; 1275():7-12. PubMed ID: 23278571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The auto-antigen repertoire in myasthenia gravis.
    Vrolix K; Fraussen J; Molenaar PC; Losen M; Somers V; Stinissen P; De Baets MH; Martínez-Martínez P
    Autoimmunity; 2010 Aug; 43(5-6):380-400. PubMed ID: 20380581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies.
    Graus YF; de Baets MH; Parren PW; Berrih-Aknin S; Wokke J; van Breda Vriesman PJ; Burton DR
    J Immunol; 1997 Feb; 158(4):1919-29. PubMed ID: 9029134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathogenic antibodies in myasthenia gravis].
    Motomura M
    Brain Nerve; 2010 Apr; 62(4):411-8. PubMed ID: 20420182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options in autoimmune myasthenia gravis.
    García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
    Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myasthenia gravis].
    Tanaka K
    Nihon Rinsho; 2004 May; 62 Suppl 5():580-5. PubMed ID: 15197988
    [No Abstract]   [Full Text] [Related]  

  • 15. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myasthenia gravis.
    Silvestri NJ; Wolfe GI
    Semin Neurol; 2012 Jul; 32(3):215-26. PubMed ID: 23117946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immune globulin in myasthenia gravis.
    Gajdos P
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis.
    Trakas N; Zisimopoulou P; Tzartos SJ
    J Neuroimmunol; 2011 Dec; 240-241():79-86. PubMed ID: 21993075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.